Thursday, 23  June  2022, 4:00-5:00 PM

Session will be held in a hybrid mode (offline at Venture Center campus and on online ZOOM platform)

Registration link:


-Understand the multidisciplinary problem solving journey

-Challenges faced during product development

-Example of diagnostic product development: insight into the process and key elements that made it successful

About the speaker: Ashutosh Shastry, PhD, Founding CTO of Evanostics

Dr. Ashutosh Shastry is a founding CTO of Evanostics and has a passion and expertise in building multidisciplinary teams, technologies, and products for diagnostics and drug delivery. Utilizing his deep experience with microsystems engineering, Dr. Shastry led the product and technology development for the Evanostics point-of-care system. Before joining Evanostics, Dr. Shastry served as Vice President of R&D at iNDx LifeCare and as the Director of Engineering at Corium International. At Corium, he led the technology development and scalable pilot manufacturing of a dissolvable-microneedles patch from early concepts to Phase IIa. Before that, he had led the development of a next-generation infusion pump, which received an Edison Award in the category of “Science & Medical Device Game Changers.” At the University of Washington, Dr. Shastry initiated research on super-hydrophobic surfaces for droplet microfluidics. Dr. Shastry has a Ph.D. in Biomedical Engineering and M.Tech and B.Tech. Degrees in Chemical Engineering from the Indian Institute of Technology Bombay. He initiated India’s first BioMEMS projects collaborating with Cancer Research Institute. He has authored numerous publications and has over fifteen patents. He has served on the Industrial Advisory Board for UCLA’s Bioengineering Department, a National Institute of Health Review Panelist for Allergy and Infectious Diseases, and the National Science Foundation SBIR Review Panel for Biomedical Technologies. As the President of EPPIC Global, he reimagined it as a place where “Technology Meets Health” and currently serves on its Board of Directors.”